The trading price of CRISPR Therapeutics AG (NASDAQ:CRSP) closed higher on Friday, May 14, closing at $101, 5.58% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $101.82 and $108.40. The company’s P/E ratio in the trailing 12-month period was 0, while its 5Y monthly beta was 2.29. In examining the 52-week price action we see that the stock hit a 52-week high of $220.2 and a 52-week low of $54.5. Over the past month, the stock has suffered -13.9% in value.
CRISPR Therapeutics AG, whose market valuation is $7.65 Billion at the time of this writing, is expected to release its quarterly earnings report Jul 26, 2021- Jul 30, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by $2.86 per share this quarter, however they have predicted annual earnings per share of -$1.15 for 2021 and -$6.36 for 2022. It means analysts are expecting annual earnings per share growth of -0.78% this year and 4.53% next year.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of CRISPR Therapeutics AG 2 upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest CRSP has a 100% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 50% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned CRSP a recommendation rating is 21. Out of them, 5 rate it a Hold, while 14 recommend Buy, whereas none assign an Outperform rating. None analyst(s) have tagged CRISPR Therapeutics AG (CRSP) as Underperform, while 2 advise Sell. Analysts have rated the stock Overweight, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 0, which symbolizes a positive outlook. A quick review shows that CRSP’s price is currently -10.19% off the SMA20 and -11.57% off the SMA50. The RSI metric on the 14-day chart is currently showing 39.76, and weekly volatility stands at 7.88%. When measured over the past 30 days, the indicator reaches 6.74%. CRISPR Therapeutics AG (NASDAQ:CRSP)’s beta value is currently sitting at 2.29, while the Average True Range indicator is currently displaying 7.65. With analysts defining $45-$220 as the low and high price targets, we arrive at a consensus price target of $158.22 for the trailing 12-month period. The current price is about -57.8% off the estimated low and 106.3% off the forecast high, based on this estimate. Investors will be thrilled if CRSP’s share price rises to $165, which is the median consensus price. At that level, CRSP’s share price would be +54.73% above current price.
To see how CRISPR Therapeutics AG stock has been performing in comparison to its peers in the industry, here are the numbers: CRSP stock’s performance was +5.58% in the latest trading, and +90.84% in the past year, while Bristol-Myers Squibb Company (BMY) has traded -0.25% on the day and positioned +1.74% higher than it was a year ago. Another comparable company Amgen Inc (AMGN) saw its stock close -0.27% lower in the most recent trading session but was up +5.63% in a year. Furthermore, Gilead Sciences Inc (GILD) showed an increase of 5.58% on the day while its price kept rising at 90.84% over the past year. CRISPR Therapeutics AG has a P/E ratio of 0, compared to Bristol-Myers Squibb Company’s 0 and Amgen Inc’s 20.82. Also in last trading session, the S&P 500 Index has surged 1.49%, while the Dow Jones Industrial also saw a positive session, up +1.06% on the day.
An evaluation of the daily trading volume of CRISPR Therapeutics AG (NASDAQ:CRSP) indicates that the 3-month average is 2.34 Million. However, this figure has declined over the past 10 days to an average of 1.5 Million.
Currently, records show that 75.77 Million of the company’s shares remain outstanding. According to Thomson Reuters data, insiders hold 12.93% of outstanding shares, whereas institutions hold 64.07%. The stats also highlight that short interest as of April 14, 2021, stood at 4.25 Million shares, resulting in a short ratio of 3.01 at that time. From this, we can conclude that short interest is 5.61% of the company’s total outstanding shares. It is noteworthy that short shares in April were up slightly from the previous month’s figure, which was 4.22 Million. However, since the stock’s price has seen -30.35% year-to-date, investors’ interest is likely to be reignited due to its potential to move higher ahead.